Eliyahou Et Al Harari Buys 1,757,469 Shares of CapsoVision (NASDAQ:CV) Stock
by Mitch Edgeman · The Markets DailyCapsoVision, Inc. (NASDAQ:CV – Get Free Report) major shareholder Eliyahou Et Al Harari bought 1,757,469 shares of the firm’s stock in a transaction on Friday, September 18th. The stock was purchased at an average cost of $5.69 per share, with a total value of $9,999,998.61. Following the completion of the transaction, the insider directly owned 1,396,494 shares of the company’s stock, valued at approximately $7,946,050.86. The trade was a -486.87% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Eliyahou Et Al Harari also recently made the following trade(s):
- On Friday, July 17th, Eliyahou Et Al Harari acquired 61,068 shares of CapsoVision stock. The stock was bought at an average price of $6.73 per share, for a total transaction of $410,987.64.
- On Wednesday, July 8th, Eliyahou Et Al Harari purchased 81,300 shares of CapsoVision stock. The shares were acquired at an average cost of $6.09 per share, for a total transaction of $495,117.00.
- On Friday, June 26th, Eliyahou Et Al Harari purchased 13,850 shares of CapsoVision stock. The shares were acquired at an average price of $7.35 per share, for a total transaction of $101,797.50.
CapsoVision Stock Down 4.0%
Shares of NASDAQ:CV traded down $0.25 during trading on Wednesday, hitting $6.05. The stock had a trading volume of 443,201 shares, compared to its average volume of 232,631. The company has a market capitalization of $302.78 million, a PE ratio of -12.87 and a beta of -2.47. The firm’s fifty day moving average is $6.41 and its 200 day moving average is $6.55. CapsoVision, Inc. has a 12 month low of $4.34 and a 12 month high of $15.37.
CapsoVision (NASDAQ:CV – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.15) EPS for the quarter. The company had revenue of $3.64 million during the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%. Equities research analysts expect that CapsoVision, Inc. will post -0.56 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on CV. Benchmark reissued a “speculative buy” rating on shares of CapsoVision in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Zacks Research upgraded CapsoVision to a “hold” rating in a report on Monday, August 31st. Finally, Roth Capital began coverage on shares of CapsoVision in a report on Friday, August 28th. They set a “buy” rating and a $9.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.50.
Hedge Funds Weigh In On CapsoVision
Large investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of CapsoVision during the second quarter worth approximately $14,372,000. Bank of New York Mellon Corp acquired a new stake in CapsoVision in the second quarter worth approximately $569,000. Deutsche Bank AG acquired a new stake in CapsoVision in the 2nd quarter valued at about $263,000. Bank of America Corp DE bought a new stake in CapsoVision during the second quarter worth approximately $193,000. Finally, Connective Capital Management LLC acquired a new position in shares of CapsoVision in the 2nd quarter worth $76,000.
About CapsoVision
CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.
The company’s principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.